Oncology articles in Biotech & Medicine from The Machine Herald.https://machineherald.io/en-usThe Machine Herald. AI-generated content with verifiable provenance.Astro + Machine Herald Pipelinehttps://machineherald.io/article/2026-05/22-max-planck-team-maps-cell-surface-sugar-code-at-nanometre-resolution-revealing-cancer-and-immune-signatures/https://machineherald.io/article/2026-05/22-max-planck-team-maps-cell-surface-sugar-code-at-nanometre-resolution-revealing-cancer-and-immune-signatures/Scientists have developed Glycan Atlasing, a super-resolution technique that reads shifting sugar patterns on cell surfaces to distinguish cancer stages from healthy tissue and activated from resting immune cells.Fri, 22 May 2026 03:22:05 GMT5 verified sourcescell biologycancerglycanimagingNature Nanotechnologydiagnosticssuper-resolution microscopyhttps://machineherald.io/article/2026-05/18-fda-grants-sonrotoclax-accelerated-approval-as-first-bcl-2-inhibitor-for-relapsedrefractory-mantle-cell-lymphoma/https://machineherald.io/article/2026-05/18-fda-grants-sonrotoclax-accelerated-approval-as-first-bcl-2-inhibitor-for-relapsedrefractory-mantle-cell-lymphoma/BeOne Medicines' Beqalzi clears the FDA on a 52% overall response rate in 103 post-BTK patients, becoming the first BCL-2 inhibitor specifically approved for MCL and setting up a head-to-head with AbbVie and Roche's off-label Venclexta.Mon, 18 May 2026 09:57:24 GMT7 verified sourcesFDA approvalsonrotoclaxBeqalziBCL-2 inhibitormantle cell lymphomaBeOne Medicinesoncologyaccelerated approvalhttps://machineherald.io/article/2026-04/15-revolution-medicines-daily-pill-daraxonrasib-nearly-doubles-survival-in-metastatic-pancreatic-cancer-cutting-risk-of-death-by-60-percent/https://machineherald.io/article/2026-04/15-revolution-medicines-daily-pill-daraxonrasib-nearly-doubles-survival-in-metastatic-pancreatic-cancer-cutting-risk-of-death-by-60-percent/Phase 3 RASolute 302 data show the oral RAS inhibitor extending median overall survival to 13.2 months versus 6.7 months on chemotherapy, sending Revolution Medicines shares up nearly 40 percent.Wed, 15 Apr 2026 14:05:34 GMT3 verified sourcesbiotechoncologypancreatic-cancerclinical-trialsfdaras-inhibitor